Nobilis Therapeutics’ NBTX-001 shows promise in treatment of patients with Panic Disorder. Study results published in Journal of Translational Medicine.

by nobilistx | Jun 14, 2017 | Uncategorized |

Nobilis Therapeutics published the results of its pioneering clinical trial on 81 patients with Panic Disorder in the Journal of Translational Medicine. Patients were treated with NBTX-001 with remarkable results. This study validates the company’s methodology...

Nobilis Therapeutics receives a notice of allowance for a patent covering treatment of psychiatric disorders with noble gases

by nobilistx | Jun 13, 2017 | Uncategorized |

Nobilis Therapeutics has received a notice of allowance for its most important patent. The patent covers the uses of noble gas-based therapies in a variety of psychiatric illnesses. Please read our press release...

Nobilis Therapeutics and Submersible Systems Partner to Create a Portable Inhalation Device for Administration of NBTX-001, a Medical Gas-based Drug Candidate

by nobilistx | May 10, 2017 | Uncategorized |

We are excited to announce a partnership with Submersible Systems  to create a portable inhalation device for administration of NBTX-001. Please click on the link to read our press...

Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial in 81 Patients with Panic Disorder

by nobilistx | May 1, 2017 | Uncategorized |

Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial. Nobilis Therapeutics, Inc. announced today the completion and formal registration of an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based...

Nobilis Therapeutics Recruits Internationally Renowned Xenon Expert to Scientific Advisory Board

http://www.marketwired.com/press-release/nobilis-therapeutics-recruits-internationally-renowned-xenon-expert-scientific-advisory-2113804.htm